» Articles » PMID: 37367888

Causal Effects of Blood Lipid Traits on Inflammatory Bowel Diseases: A Mendelian Randomization Study

Overview
Journal Metabolites
Publisher MDPI
Date 2023 Jun 27
PMID 37367888
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC), have become a global health problem with a rapid growth of incidence in newly industrialized countries. Observational studies have recognized associations between blood lipid traits and IBDs, but the causality still remains unclear. To determine the causal effects of blood lipid traits, including triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) on IBDs, two-sample Mendelian randomization (MR) analyses were conducted using the summary-level genome-wide association study (GWAS) statistics of blood lipid traits and IBDs. Our univariable MR using multiplicative random-effect inverse-variance weight (IVW) method identified TC (OR: 0.674; 95% CI: 0.554, 0.820; < 0.00625) and LDL-C (OR: 0.685; 95% CI: 0.546, 0.858; < 0.00625) as protective factors of UC. The result of our multivariable MR analysis further provided suggestive evidence of the protective effect of TC on UC risk (OR: 0.147; 95% CI: 0.025, 0.883; < 0.05). Finally, our MR-BMA analysis prioritized TG (MIP: 0.336; θ^: -0.025; PP: 0.31; θ^: -0.072) and HDL-C (MIP: 0.254; θ^: -0.011; PP: 0.232; θ^: -0.04) for CD and TC (MIP: 0.721; θ^: -0.257; PP: 0.648; θ^: -0.356) and LDL-C (MIP: 0.31; θ^: -0.095; PP: 0.256; θ^: -0.344) for UC as the top-ranked protective factors. In conclusion, the causal effect of TC for UC prevention was robust across all of our MR approaches, which provide the first evidence that genetically determined TC is causally associated with reduced risk of UC. The finding of this study provides important insights into the metabolic regulation of IBDs and potential metabolites targeting strategies for IBDs intervention.

Citing Articles

Mendelian randomisation analysis for intestinal disease: achievement and future.

Ruan X, Che T, Chen X, Sun Y, Fu T, Yuan S eGastroenterology. 2025; 2(2):e100058.

PMID: 39944470 PMC: 11770446. DOI: 10.1136/egastro-2023-100058.


To explore the causal association between the serum lipid profile and inflammatory bowel disease using bidirectional Mendelian randomisation analysis.

Pang X, Yang H, Li M, Suarez-Farinas M, Tian S eGastroenterology. 2025; 2(2):e100034.

PMID: 39944468 PMC: 11770443. DOI: 10.1136/egastro-2023-100034.


The relationship between inflammatory bowel disease and sarcopenia-related traits: a bidirectional two-sample mendelian randomization study.

Sun Z, Liu G, Xu J, Zhang X, Wei H, Wu G Front Endocrinol (Lausanne). 2024; 15:1402551.

PMID: 39072277 PMC: 11272465. DOI: 10.3389/fendo.2024.1402551.


Investigating genetic links between blood metabolites and preeclampsia.

Lin Q, Li S, Wang H, Zhou W BMC Womens Health. 2024; 24(1):223.

PMID: 38580943 PMC: 10996307. DOI: 10.1186/s12905-024-03000-7.


Blood glucose and lipids are associated with sarcoidosis: findings from observational and mendelian randomization studies.

Zhan Y, Zhang J, Yang R, Deng Z, Chen S, Feng J Respir Res. 2024; 25(1):50.

PMID: 38254098 PMC: 10804582. DOI: 10.1186/s12931-023-02663-4.

References
1.
Sanderson E, Davey Smith G, Windmeijer F, Bowden J . An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol. 2018; 48(3):713-727. PMC: 6734942. DOI: 10.1093/ije/dyy262. View

2.
Zhao M, Feng R, Ben-Horin S, Zhuang X, Tian Z, Li X . Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. Aliment Pharmacol Ther. 2021; 55(3):266-276. DOI: 10.1111/apt.16703. View

3.
McIntyre N, Isselbacher K . Role of the small intestine in cholesterol metabolism. Am J Clin Nutr. 1973; 26(6):647-56. DOI: 10.1093/ajcn/26.6.647. View

4.
Gkouskou K, Deligianni C, Tsatsanis C, Eliopoulos A . The gut microbiota in mouse models of inflammatory bowel disease. Front Cell Infect Microbiol. 2014; 4:28. PMC: 3937555. DOI: 10.3389/fcimb.2014.00028. View

5.
Aarestrup J, Jess T, Kobylecki C, Nordestgaard B, Allin K . Cardiovascular Risk Profile Among Patients With Inflammatory Bowel Disease: A Population-based Study of More Than 100 000 Individuals. J Crohns Colitis. 2018; 13(3):319-323. DOI: 10.1093/ecco-jcc/jjy164. View